8-K: NeuroPace Reports Record Quarterly Revenue and Provides Strong 2025 Guidance

NeuroPace announces strong Q4 2024 and full-year results, highlighted by record quarterly revenue and positive guidance for 2025, alongside a strategic public offering and repurchase of KCK holdings.

Summary

• NeuroPace reported a 19% year-over-year increase in Q4 2024 revenue, reaching $21.5 million.
• Full-year 2024 revenue grew by 22% to $79.9 million, compared to $65.4 million in 2023.
• The company's gross margin remained strong at 73.9% for the full year 2024.
• NeuroPace completed a public offering in February 2025, raising net proceeds of approximately $20.2 million.
• A portion of the proceeds, $49.5 million, was used to repurchase shares from KCK Ltd.
• The company anticipates revenue between $92 million and $96 million for 2025, representing a growth of 15% to 20%.
• NeuroPace expects to achieve cash flow breakeven with its current cash balance.
• The NAUTILUS pivotal study is on track, with FDA submission planned for the second half of 2025.
• The company is advancing product development programs focused on AI-enabled software and a next-generation platform.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, successful capital raising, and promising future guidance. The company's strategic initiatives and product development programs contribute to a favorable sentiment.

Positives

• Record quarterly revenue of $21.5 million in Q4 2024.
• Full-year 2024 revenue increased by 22% to $79.9 million.
• Strong gross margin at 73.9% for 2024.
• Successful public offering completed in February 2025.
• Repurchase of shares from KCK Ltd., removing a potential share overhang.
• Anticipated revenue growth of 15% 20% for 2025.
• Expectation to achieve cash flow breakeven.
• Advancement of clinical and product development programs.

Negatives

• The company reported a net loss of $5.3 million for the fourth quarter of 2024.
• The company reported a net loss of $27.1 million for the full year of 2024.
• Cash, cash equivalents, and short-term investments decreased from $56.8 million to $52.8 million during Q4 2024.

Risks

• Market acceptance and adoption of the RNS System could impact revenue.
• Operating expenses could be higher than anticipated, potentially affecting cash resources.
• Gross margin may be lower than forecast.
• Pricing of the RNS System and reimbursement availability pose risks.
• Regulatory submissions and approvals may face uncertainties.
• Product development, especially AI-powered software, carries inherent risks.
• Reliance on third parties, including single-source suppliers, could be problematic.
• The distribution agreement with DIXI Medical may not be renewed.

Future Outlook

NeuroPace anticipates revenue between $92 million and $96 million for 2025, representing a growth of 15% to 20%. The company expects to achieve cash flow breakeven and is focused on expanding access to and indications for the RNS System.

Management Comments

• 'We are pleased with the strong revenue growth reported in 2024, as we continue to implement our long-range plan aimed at expanding access to and indications for the RNS System,' said Joel Becker, Chief Executive Officer of NeuroPace.
• Management believes they have sufficient cash to support current plans and achieve cash flow breakeven.

Industry Context

NeuroPace operates in the medical device industry, specifically focusing on epilepsy treatment. The company's RNS System is a unique, brain-responsive platform. The expansion of indications and development of AI-enabled software align with industry trends towards personalized and data-driven healthcare solutions.

Comparison to Industry Standards

• Comparing NeuroPace to companies like Medtronic or Boston Scientific, which also have a presence in neuromodulation, NeuroPace's focus is more niche, targeting drug-resistant epilepsy.
• While Medtronic's Vanta recharge-free neurostimulator offers a 11-15 year battery life, NeuroPace's RNS system offers a unique closed-loop approach.
• Unlike companies like LivaNova, which offers vagus nerve stimulation (VNS) therapy, NeuroPace's RNS system directly targets seizure onset zones in the brain.
• NeuroPace's gross margin of 73.9% is competitive with larger medical device companies, indicating efficient operations.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and growth prospects.
• Patients will benefit from the expanded access to and indications for the RNS System.
• Employees will benefit from the company's continued growth and success.
• The company's financial stability strengthens its relationships with suppliers and creditors.

Next Steps

• Complete one-year patient follow-up visits for the NAUTILUS pivotal study in March 2025.
• Submit the NAUTILUS study to the FDA in the second half of 2025.
• Present data from the Post-approval Study of the RNS System at the American Academy of Neurology meeting in April 2025.
• Advance product development programs focused on AI-enabled software and a next-generation platform.
• Submit data from the NEST program to the FDA in the second half of 2025 to support an expansion in indication for use.

Key Dates